Home・Список акций・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Закрыт

СекторЗдравоохранение

3.16 6.76

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.94

Макс.

3.29

Ключевые показатели
By Trading Economics
Доход	4.1M -5.7M
Прибыль на акцию	-0.13
Сотрудники	34
EBITDA	4.2M -5.7M

Дивиденды
By Acuity
Следующий отчет о доходах	11 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-157M 232M
Предыдущая цена открытия	-3.6
Предыдущая цена закрытия	3.16

Новостные настроения

By Acuity

50%

151 / 340 Рейтинг в Healthcare

Anavex Life Sciences Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

30 июл. 2026 г., 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

29 июл. 2026 г., 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

28 июл. 2026 г., 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

27 июл. 2026 г., 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

24 июл. 2026 г., 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

21 июл. 2026 г., 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Сравнение c конкурентами

Изменение цены

Anavex Life Sciences Corp Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

Покупка

Удержание

Продажа

Основано на мнении 0 аналитиков, присваивавших рейтинги акциям Anavex Life Sciences Corp – Данные за последние 3 месяца.

Настроения

By Acuity

151 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.